NSE · MADHAVBAUG
Vaidya Sane Ayurved Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹92 Cr with net profit ₹7 Cr — a 7.8% net margin, versus 1.96% the period before.
Shareholding
As of 2026-03-31
- Promoter66.34%
- Public33.66%
671 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.23× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Healthcare · ranked #1 of 79 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.06 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.33 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,931 Cr | 752.83 | 14.2 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.48 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Vaidya Sane Ayurved Laboratories Ltd.(this company) | — | 40.92 | 2.51 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashVaidya Sane Ayurved Laboratories Ltd. (MADHAVBAUG) has a market capitalization of Rs 156 Cr and reported revenue of Rs 91.7 Cr. The company's PE ratio is 44.14, with an EPS of 4.69. The book value stands at Rs 76.47, and the debt-to-equity ratio is 0.03.
Positives
- +The debt-to-equity ratio is low at 0.03.
- +Promoter holding is stable at 66.3369% as of March 31, 2026.
- +Promoter pledges are 0%, indicating no shares are pledged.
Negatives
- −Revenue decreased by 9.5% to Rs 91.7 Cr.
- −The company is under ESM · ESM 1 surveillance.
- −Return on Equity (ROE) is not available in the provided data.
Financial Performance
The company's revenue decreased by 9.5% to Rs 91.7 Cr. Net profit for the year ending Mar 2025 was Rs 7.1539 Cr, up from Rs 1.9804 Cr in Mar 2024. Earnings per share (EPS) for Mar 2025 was Rs 5.81, compared to Rs 1.75 in Mar 2024.
Profitability & Returns
The Return on Capital Employed (ROCE) is 13.28%. The net profit for the period ending Mar 2025 was Rs 7.1539 Cr, with EPS at Rs 5.81. The EBITDA for the same period was Rs 11.2058 Cr.
Balance Sheet
The company's debt-to-equity ratio is 0.03, indicating a low level of debt. The book value per share is Rs 76.47. No specific details about current assets, liabilities, or cash flows are available in the provided data.
Ownership & Pledges
There are no shares pledged by the promoters, with promoter pledge at 0%. DII and FII holdings remain at 0%.
Regulatory & Surveillance
The company is under ESM · ESM 1 surveillance measures. This includes enhanced monitoring by regulatory bodies due to certain criteria being met. No other specific regulatory actions or notices are provided.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Vaidya Sane Ayurved Laboratories Ltd.share price & fundamentals